Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Laurence Heripret"'
Autor:
Jacques Durant, Yannick Le Marchand-Brustel, Pierre Dellamonica, Bernard Binétruy, Christophe Perrin, Laurence Heripret, Myriam Aouadi, Rodolphe Garraffo, Matthieu Prot, Thibaud Lavrut, Nathalie Cardot-Leccia
Publikováno v:
Antimicrobial Agents and Chemotherapy. 50:3998-4004
Highly active antiretroviral therapy (HAART) of human immunodeficiency virus-infected patients is associated with adverse effects, such as lipodystrophy and hyperlipidemia. The lipodystrophic syndrome is characterized by a peripheral lipoatrophy and/
Autor:
Laurence Heripret, Ghislaine Leleu, Corinne Merle De Boever, Martine Troccaz, Juliette Pavie, Jean-Michel Molina, Anne-Geneviève Marcelin, Ai Jaguar Study Team
Publikováno v:
The Journal of Infectious Diseases. 191:840-847
The antiviral efficacy of didanosine in patients experiencing virological failure is not well known.A total of 168 patients (139 men and 29 women) receiving stable antiretroviral therapy with plasma human immunodeficiency virus type 1 (HIV-1) RNA lev
Autor:
Jacques Durant, Laurence Heripret, Brigitte Dunais, Thibaud Lavrut, Marie-Ange Sérini, Pierre Dellamonica, Rodolphe Garraffo
Publikováno v:
Clinical Drug Investigation. 25:643-650
Objective: Most of the newer fluoroquinolones are active against bacteria such as Streptococcus pneumoniae and Staphylococcus aureus, which are able to multiply inside polymorphonuclear leukocytes (PMNs). The aim of this study was to determine moxifl
Autor:
Marie-Claire Nevers, Jacques Grassi, Rodolphe Garraffo, Jacques Durant, Danièle Duval, Christophe Créminon, Roger Guedj, Stéphane Azoulay, Laurence Heripret, Pierre Dellamonica
Publikováno v:
Journal of Immunological Methods. 295:37-48
The protease inhibitor lopinavir (LPV; [1S-[1R*(R*), 3R*,4R*]]-N-[4-[[(2,6-dimethylphenoxy)-acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl) pentyl] tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimide acetamide) is widely used in anti-human immuno
Autor:
Dominique Salmon, Philippe Morlat, Fabrice Bonnet, Sibylle Bevilacqua, Laurence Heripret, Dominique Costagliola, Geneviève Chêne, Charlotte Lewden, Eric Jougla, Thierry May
Publikováno v:
Cancer. 101:317-324
Autor:
Fabrice Bonnet, Charlotte Lewden, Thierry May, Laurence Heripret, Eric Jougla, Sibylle Bevilacqua, Dominique Costagliola, Dominique Salmon, Geneviève Chêne, Philippe Morlat, null THE MORTALITÉ 2000 STUDY GROUP
Publikováno v:
Scandinavian journal of infectious diseases. 37(6-7)
The objective of the study was to describe the underlying causes of death of HIV-infected patients in the HAART era and to focus on those related to opportunistic infection (OI), in a national multicentre study ('Mortalite 2000'). A total of 964 deat
Autor:
Sibylle Bevilacqua, Laurence Heripret, Dominique Salmon-Ceron, Philippe Morlat, Geneviève Chêne, Charlotte Lewden, Eric Jougla, Thierry May, Dominique Costagliola, Fabrice Bonnet
Publikováno v:
Journal of hepatology. 42(6)
Background/Aims We analyzed the characteristics of HIV infected patients who died from liver disease, focusing on hepatitis virus co-infection. Methods One-hundred and eighty-five French hospital departments involved in HIV/AIDS management prospectiv
Autor:
Philippe Morlat, Geneviève Chêne, Eric Jougla, Charlotte Lewden, Laurence Heripret, Thierry May, Dominique Salmon, Fabrice Bonnet, Sibylle Bevilacqua, Dominique Costagliola
Publikováno v:
International journal of epidemiology. 34(1)
Background In the era of highly active antiretroviral therapy (HAART) mortality has decreased substantially among human immunodeficiency virus (HIV)-infected people with access to HAART, but there are concerns regarding co-morbidities and adverse eff
Autor:
Fabrice, Bonnet, Charlotte, Lewden, Thierry, May, Laurence, Heripret, Eric, Jougla, Sibylle, Bevilacqua, Dominique, Costagliola, Dominique, Salmon, Geneviève, Chêne, Philippe, Morlat
Publikováno v:
Cancer. 101(2)
Before the introduction of highly active antiretroviral therapy (HAART), malignancies accounted for less than 10% of all deaths among human immunodeficiency virus (HIV)-infected patients. This figure may have increased, and the observed types of mali
Autor:
Marie-Claire Nevers, Stéphane Azoulay, Jacques Durant, Jacques Grassi, Danièle Duval, Christophe Créminon, Laurence Heripret, Roger Guedj, Pierre Dellamonica
Nevirapine (Viramune) (NVP) is a nonnucleoside reverse-transcriptase inhibitor indicated for the treatment of human immunodeficiency virus (HIV) type 1 infection. It represents an attractive option for patients who prefer a protease-sparing regimen,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92fc04f281d25bc35fbdb51a013f95d3
https://europepmc.org/articles/PMC310181/
https://europepmc.org/articles/PMC310181/